guest ::
| Home > Articles > Published articles > Low-dose statin treatment increases prostate cancer aggressiveness |
| Home > Articles > Published articles > Low-dose statin treatment increases prostate cancer aggressiveness |
(CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) (Centro de Investigación Biomédica en Red de Cáncer) (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) (Biochemistry and Molecular Biology Department, University of the Basque Country, Bilbao, Spain) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (IKERBASQUE, Basque foundation for science, Bilbao, Spain)| Date: | 2017 |
| Abstract: | Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer. |
| Grants: | Instituto de Salud Carlos III PI10-01484 Instituto de Salud Carlos III PI13-00031 European Commission 660191 Ministerio de Economía y Competitividad SAF2016-79381-R Ministerio de Economía y Competitividad 660191 |
| Note: | Altres ajuts: NM-M was supported by the Spanish Association Against Cancer (AECC), AECC JP Vizcaya. VT is supported by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the department of health of the Basque Government (2016111109) and the 2016 grant of the AECC (Junta provincial de Bizkaia). LA, AA-A and LV-J were supported by the Basque Government of education. The work of A.C. is supported by the Ramón y Cajal award, the Basque Department of Industry, Tourism and Trade (Etortek) and the department of education (IKERTALDE IT1106-16), FERO VIII Fellowship, the BBVA foundation, Severo Ochoa. Excellence Accreditation SEV-2016-0644) and the European Research Council (Starting Grant 336343; Proof of Concept 754627). The participation of AC, VT, NM-M, SF and AZ as part of CIBERONC was co-funded with FEDER funds. |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Subject: | Prostate cancer ; Statins ; Cholesterol ; Obesity ; Mouse models |
| Published in: | Oncotarget, Vol. 9 (october 2017) , p. 1494-1504, ISSN 1949-2553 |
